Animal Studies Demonstrate Efficacy in Treatment of Non-Small Cell Lung Cancer
May 23, 2014
Batu Biologics, a biopharmaceutical company focused on the development and commercialization of cell therapies in the area of immune modulation, is pleased to announce the filing of U.S. patent application (61/987657) covering the composition and application of its flagship product, Vallovax. The novel cancer vaccine is specifically formulated to target the blood vessels that supply the tumor through induction of tumor autoimmunity and immune stimulation.
“Angiogenesis has proven to be a key factor in the proliferation of tumor cells within the host. Recent studies have revealed that without the formation of new blood vessels, tumors are unable to receive the blood supply they need to grow bigger than 1 to 2 mm in diameter,” commented Andy J. Kim, Vice President of Scientific Research at Batu Biologics. “Testimony to the power of angiogenic blockade is the drug Avastin, which last quarter had sales of $1.6 billion. Unfortunately, existing drugs that block angiogenesis only target specific pathways of this process, thus making them not universally applicable. An example of this is the withdrawal of FDA approval for treating metastatic breast cancer with Avastin in 2010. In contrast to previous approaches targeting cancer endothelium, Vallovax harnesses the power of the immune response, which allows for memory, specificity, and adaptability.”
The Vallovax platform builds upon the work of Dr. Valentine Govallo, who recognized the placenta as one of the only natural systems that mimics cancer through immune suppression, angiogenesis, and metastasis. The “Govallo Vaccine”, an uncharacterized placenta-based cancer immunotherapy, exhibited remarkable rates of remission: 66.7% 10-year survival rates for lung cancer patients. Through recent developments in cancer research, Batu Biologics has identified and isolated the cells found in the “Govallo Vaccine” that combat angiogenesis and metastasis in cancer and plan to file an Investigational New Drug (IND) Application for non-small stage lung cancer to the FDA in 2014.
“Our Team is motivated to bring novel therapeutics to the forefront of medical research that use the power of the body’s own immune system to extend life expectancy,” commented Samuel C. Wagner, President and CEO. “Batu Biologics looks to pioneer the emerging field of cell therapy with novel therapeutics that improve the quality of life for late-stage patients with minimal toxic side-effects.”
About Batu Biologics: Batu Biologics is a preclinical biopharmaceutical company focusing on developing and commercializing allogeneic cell therapies in the area of immune modulation. Our products are centered around the idea of creating or breaking immune tolerance. The company is currently in the preclinical stages of drug development for its two flagship products: Immstem and Vallovax. Batu Biologics has filed two provisional patents in the field of cancer immunotherapy and plans to significantly expand its IP in 2014.
9255 Towne Centre Drive
San Diego, CA 92121